Abstract: Laboratory in vitro evolution (LIVE) might deliver DNAa ptamers that bind proteins expressed on the surface of cells.Inthis work, we used cell engineering to place glypican 3 (GPC3), apossible marker for liver cancer theranostics,onthe surface of aliver cell line.Libraries were then built from asixletter genetic alphabet containing the standardnucleobases and two added nucleobases (2-amino-8H-imidazo[1,2-a]-[1,3,5]triazin-4-one and 6-amino-5-nitropyridin-2-one), Watson-Crick complements from an artificially expanded genetic information system (AEGIS). With counterselection against non-engineered cells,e ight AEGIS-containing aptamers were recovered. Five bound selectively to GPC3-overexpressing cells.T his selection-counterselection scheme had acceptable statistics,n otwithstanding the possibility that cells engineered to overexpress GPC3 might also express different off-target proteins.T his is the first example of such ac ombination.
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Researchers in biomolecular chemistry frequently need reagents that bind selectively to proteins,e specially those on the surfaces of cells.S uch reagents are very often antibodies.A side from their biological complexity,a ntibody generation offers no easy way to generate areagent that binds to the target in ac ell-surface context. Therefore,a lternative approaches have been suggested to replace antibodies as binding reagents.For example,libraries of DNA/RNAcan be presented to at arget protein displayed on cell surfaces. Library components that bind to the protein are recovered and PCR-amplified, perhaps with mutation, to give adaughter generation of "survivors" enriched in binding species. Repeating this cycle gives aptamers with improved binding in ap rocess known as "in vitro selection", [1] "systematic evolution of ligands by exponential enrichment" (SELEX), [2] or, if mutation is involved, "laboratory in vitro evolution" (LIVE). [3] However,a ptamers have not replaced antibodies in cell biology,m ost likely owing to their poor affinities.T hese are often attributed to the limited repertoire of functional groups available on standard DNA/RNA, especially when compared to the repertoire available to proteins that contribute to binding.
[3] Fore xample,s tandard DNA/RNAh as no positively charged groups (e.g., lysine and arginine), carboxylate groups (e.g., aspartate and glutamate), and ageneral-purpose acid-base catalyst (histidine) group,w hich are commonly found in the standard 20 amino acids.
Fortunately,synthetic biology has expanded the potential of LIVE by creating artificially expanded genetic information systems (AEGIS). AEGIS is at ype of DNA/RNAw ith additional nucleotides and additional functionality.A EGIS rearranges hydrogen-bonding groups to allow DNA/RNAt o contain as many as twelve independently replicable building blocks. [4] AEGIS supports six-letter LIVE ( Figure 1A ), where one of the added nucleotides (2-amino-8H-imidazo- [1,2-a] [1, 3, 5] triazin-4-one,Z )h as an itro group,auniversal binding unit that supports polyvalent interactions (compare nitrocellulose,for example). Previous studies suggest that this might increase the richness of an AEGIS library as areservoir for binding aptamers,a lthough direct comparisons are difficult to do. [3] Herein, we asked whether AEGIS-LIVE might be expanded to target specific proteins in acell-surface context. This would require that we a) engineer arecombinant cell so that it expresses the target protein abundantly on its surface, b) perform ac ell-based LIVE using as ix-letter GACTZP library (P = 6-amino-5-nitropyridin-2-one), and c) recover aptamers that bind to the cell for downstream analysis.
We have combined these three steps using glypican 3 (GPC3) as ap rotein target. GPC3 may be as pecific biomarker for hepatocellular carcinoma (HCC).
[5] Upregulated in most HCCs,i ti sa bsent from primary hepatocytes, cirrhotic cells,a nd benign lesions. [6] As liver cancer progresses,G PC3 may stimulate several oncogenic signaling pathways. [7] Monoclonal antibodies (mAbs) are known for GPC3, recognizing different epitopes on the core protein. [5a,c] Some are being examined as potential therapeutic agents through their binding to GPC3. [8] These considerations suggest that AEGIS aptamers might also have clinical use,where intrinsic advantages of aptamers over antibodies might be exploited. [9] Aptamers (typically 10-100 nucleotides (nts)) are generally smaller than antibodies, easier to renature,c heaper to develop,c heaper to produce, and more stable to unfolding.Furthermore,facile reselection and combination afford DNA/RNAaptamers with increasing affinity,even in the nanomolar range,through SELEX/LIVE ( Figure 1B ).
However,t argeting cells that naturally express GPC3 would almost certainly generate aptamers that bind other surface proteins as well as those that bind GPC3. Whereas aptamers that bind off-target might be removed by acounterselection targeting the same type of natural cell lacking GPC3, it is hard to know where to find such acell. Conversely, engineering cells to overexpress at arget protein has ar isk: While the engineering process can generally deliver at arget protein to asurface,itmight also alter other surface markers, with selection-counterselection strategies giving aptamers against other targets ( Figure 1B) .
To explore the statistics of the cell-engineering strategy, we started with am urine cell line (BNL 1ME A. 7R.1; 1MEA) that does not express murine GPC3 (mGPC3; Figure 2 ), ac ell useful for counterselection. We then transfected 1MEA with aplasmid carrying the human GPC3 gene (hGPC3) with agene conferring neomycin resistance (NEO). Cells expressing hGPC3 (1MEA hGPC3 )w ere obtained by screening for resistance to the geneticin-selective antibiotic (G418 sulfate). hGPC3 expression was confirmed in mRNA (by RT-PCR) and protein (western blotting) levels.Immunocytochemistry (ICC) confirmed that hGPC3 is abundantly expressed on the surface of 1MEA engineered cells ( Figure 2 ). TheG PC3-overexpressing 1MEA hGPC3 cells were then used as targets for AEGIS-LIVE, with 1MEA cells used for counterselection. As ix-letter AEGIS-DNAl ibrary was synthesized from phosphoramidite mixtures (T/G/A/C/Z/P % 1:1:1:1:2:2), with a3 5ntr andomized region flanked by two 18 nt primer binding sites (see the Supporting Information, Table S1 ). TheA EGIS-DNAl ibrary (20 nmol) was incubated with 1MEA hGPC3 cells (at 4 8 8Cf or 30 min). Unbound DNAo ligonucleotides were then removed, bound ones were recovered, and acounterselection process (starting at round 5) was applied to the survivors.F ollowing counterselection, survivors that bound GPC3-positive cells,b ut not 1MEA cells,w ere PCR-amplified [10a] (Table S2) . Singlestranded AEGIS-DNAa mplicons enriched in molecules having these dual binding features (Table S3) were recovered, and the selection cycle was repeated. Starting from round nine,two cycles of negative selection were conducted for each round of positive selection. Selection stringencyw as increased by using fewer cells and shorter incubation times. Enrichment of binding DNAoligonucleotides was monitored by flow cytometry with 5'-fluorescein tags ( Figure S1 ).
After eleven rounds,s ignificant fluorescence was observed for GPC3-positive cells.Incontrast, GPC3-negative cells showed little fluorescence.A EGIS-LIVE was stopped, and the survivor library from round 10 was PCR-amplified. Thea mplicons were then transliterated for six-letter AEGIS deep sequencing [10] (Table S4 ). Thee leven most abundant motifs contributed from 0.91 to 11.6 %t ot he total survivor population (Table S5) . These were resynthesized with 5'-biotin tags.
Binding of biotinylated aptamer candidates was compared for transfected1 MEA hGPC3 cells andu ntransfected 1MEA cells (30 min,48 8C, 250 nm). Aphycoerythrin(PE) streptavidin conjugate generated the observed fluorescence.T he extentof celll abelingw as determined by flowc ytometry. Figure 3A shows the number of cells having thei ndicated level of labeling,the "effective number" of GPC3sites per cell.
We then assessed the binding statistics,r ecognizing that the overexpression of GPC3 in the engineered cells might alter the level or kind of proteins displayed on their surface relative to the non-engineered cells.Interestingly,products 2, 3, 4, 5, 7, 8, 9 ,a nd 11 (LG1-LG8,F igure 3B)a ll showed substantial binding to the engineered target cells.H owever, aptamers LG1, LG2,a nd LG4 also showed binding to the untransfected "negative" cells.T his thus provides ab uilt-in metric for determining the success of the transfectionuntransfection strategy.W eh ypothesized that LG1, LG2, and LG4 bind to proteins other than GPC3 that were presented by the engineered cells,p erhaps in amounts different from the surface of non-engineered cells,w hich might be aconsequence of the engineering.
We then tested the ability of GPC3 cell-specific aptamers to bind other cells,including the hGPC3-positive human liver cancer cell lines HepG2, Huh7, and Hep3B,t he mGPC3-positive liver cancer line Hepa1-6, the hGPC3-negative human liver cancer lines LH86 and SK-Hep1, and the hGPC3-negative non-cancerous human liver cell line Hu1545 ( Figure S2 ). Aptamers LG5, LG6,a nd LG7 showed substantial binding to all four GPC3-positive cells.Aptamers
LG3 and LG8 showed binding to HepG2, Hep3B,and Hepa1-6c ells.H owever, LG3 and LG8 were not observed to significantly bind HuH7 cells ( Table 1) . None of the five aptamers bound to GPC3-negative SK-Hep1, LH86, and Hu1545 cells.
Next, the apparent dissociation constants (K d )for HepG2 cells were estimated for individual AEGIS aptamers using different concentrations (0.1-1000 nm)ofbiotinylated aptamers,w ith fluorescence coming from PE conjugated with streptavidin. Thebest aptamer, LG5,had a K d value of 6nm. Theo ther K d values were in the range of 60-500 nm (Figure S3) . To show that the AEGIS nucleotides were essential for binding in LG5,their analogues of replacing Zwith A, T, G, Cw ere tested, and none of them showed any binding ( Figure S4 ), demonstrating the significant role of Zi n aptamer LG5.
We then asked whether these aptamers would compete with an anti-hGPC3 antibody generated against hGPC3. Here,h igh concentrations (2.5 mm)o ft he aptamer were incubated with HepG2 cells followed by incubation with the antibody (250 nm). Thea ptamers were not displaced by the antibodies ( Figure S5 ). This is perhaps not surprising as the details of aptamer selection and antibody selection are sufficiently different that one might not expect the two processes to find the same epitopes.
To obtain further evidence that the selected aptamers bind to surface GPC3 ( Figure 4A ), the hGPC3-positive HepG2 cells were lysed, biotinylated aptamers were added in parallel with ab iotinylated random DNAs equence (RS), and the biotinylated aptamers (RS)/lysate complexes were recovered on streptavidin-modified magnetic beads.Recovered protein was analyzed by SDS-PAGEa nd western blotting with antihGPC3 mAb.F igure 4B shows that LG5, LG6,a nd LG7 captured hGPC3 from HepG2 cell lysate.S ome nonspecific binding was also seen between RS and hGPC3.
LG3 and LG8 showed no selective binding, which is possibly due to their higher dissociation constants ( Figure S3 ).
AEGIS-LIVE is in its infancyt oc reate ligands for proteins "on demand". Much work remains to be done to LG3 ++À +
show how generally the added information density and added functionality of AEGIS libraries can improve their richness as reservoirs compared to standard libraries.A dding functionality alone appears to have worked for expanding SELEX as done by SomaLogic,where all four standard nucleotides carry functionality to give SomaMers. [11] Click-SELEX is also an elegant way to add functionality. [12] These methods do not, of course,h ave additional information density.H owever, work by Hirao and co-workers with extra nucleotides does expand the alphabet, and also appears to improve aptamer performance. [13] From at echnical perspective,w eb elieve this to be the most successful AEGIS-LIVE system reported to date.Given the novelty of the AEGIS nucleotides and that polymerases have ap ropensity to reject unnatural nucleotides,i tr emains ac hallenge to retain them through many PCR cycles.H ere, however, retention was the highest yet seen, perhaps because of improved AEGIS PCR or perhaps because of the higher amounts of AEGIS nucleotides in the original library. Furthermore,t hese results confirm that aptamers containing Zand Pcan have excellent affinities in the nanomolar range, the range of the very best GACT aptamers.
In summary,aseries of six-nucleotide aptamers have been found to target cells engineered to overexpress aspecific cellsurface protein, with the non-engineered cell serving in ac ounterselection. These aptamers could be used to distinguish cells that display that protein from those that do not, and might thus become useful for hGPC3 detection and therapy.
